Submitted by [email protected] on Wed, 08/12/2020 - 12:00 PM
CARB-X is awarding up to US$2.91 million to Evotec SE, a drug discovery and development company in Germany, to develop a new class of antibiotics to treat infections caused by deadly multidrug-resistant Gram-positive and Gram-negative bacteria.
Content Source: CARB-X
Content Author: CARB-X
Submitted by [email protected] on Thu, 07/30/2020 - 12:00 PM
Britain and India are expanding their existing scientific research collaboration with five new projects to tackle anti-microbial resistance (AMR) that could lead to important advances in the global fight against antibiotic-resistant bacteria and genes. The five projects are planned to start in September 2020. The UK is contributing £4 million from the UK Research and Innovation Fund for International Collaboration, and India is matching this with its own resources (£8 million in total).
Content Source: United Kingdom
Content Author: United Kingdom
Submitted by [email protected] on Fri, 09/20/2019 - 12:00 PM
Dutch and US researchers have re-engineered non-druggable compounds that block the transmission and metabolism of the malaria parasite Plasmodium falciparum.
Content Source: European Biotechnology
Content Author: TG
Submitted by [email protected] on Thu, 07/25/2019 - 12:27 PM
Content Source: US Department of Health and Human Services (HHS)
Submitted by [email protected] on Thu, 05/02/2019 - 12:00 PM
Although new antibiotics are very much needed, they will only be most effective if they’re used sparingly — for the most critical of cases. This presents serious economic challenges to developing antibiotics.
Content Source: STAT
Content Author: Meghan Keshavan
Submitted by [email protected] on Thu, 03/07/2019 - 12:00 PM
The development and ultimate approval of tecovirimat for the antiviral treatment of smallpox, a disease that has been eradicated from the world for nearly 40 years, required a unique regulatory approach based on the US Food and Drug Administration's Animal Rule.
Content Source: Lancet
Content Author: Kirk M Chan-Tack, Patrick R Harrington, Su-Young Choi
Submitted by [email protected] on Wed, 02/06/2019 - 08:50 AM
Content Source: SMI Group
Submitted by [email protected] on Mon, 01/14/2019 - 12:00 PM
Using computer modelling, researchers were able to identify new drugs by building a reliable replica of the bacterial protein and then working out what the best orientation is for the drug to fit in the bacterial protein.
Content Source: MedicalXpress
Content Author: Ruben Cloete
Submitted by [email protected] on Thu, 11/29/2018 - 08:48 AM
Content Source: Wellcome Centre for Anti-Infectives Research
Submitted by [email protected] on Fri, 10/12/2018 - 12:00 PM
Accepting that antibiotics are infrastructure would change our relationship to the drugs, forcing us to recognize that medicine requires long-term planning.
Content Source: Wired
Content Author: Maryn McKenna